Free Trial
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free MBX Stock Alerts

Microbix Biosystems (MBX) Competitors

Microbix Biosystems logo
C$0.30 0.00 (0.00%)
As of 06/12/2026 03:50 PM Eastern
Compare

MBX vs. HBP, SCYB, COM, NVH, and IGX

Should you buy Microbix Biosystems stock or one of its competitors? MarketBeat compares Microbix Biosystems with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Microbix Biosystems include Helix BioPharma (HBP), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), and IntelGenx Technologies (IGX). These companies are all part of the "biotechnology" industry.

How does Microbix Biosystems compare to Helix BioPharma?

Helix BioPharma (TSE:HBP) and Microbix Biosystems (TSE:MBX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

Helix BioPharma has a beta of 0.421776, suggesting that its stock price is 58% less volatile than the broader market. Comparatively, Microbix Biosystems has a beta of 0.70266, suggesting that its stock price is 30% less volatile than the broader market.

Helix BioPharma has a net margin of 0.00% compared to Microbix Biosystems' net margin of -38.62%. Microbix Biosystems' return on equity of -21.02% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -36.79% -279.98%
Microbix Biosystems -38.62%-21.02%3.82%

Microbix Biosystems has higher revenue and earnings than Helix BioPharma. Helix BioPharma is trading at a lower price-to-earnings ratio than Microbix Biosystems, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.06N/A
Microbix BiosystemsC$14.81M2.78C$3.39M-C$0.04N/A

In the previous week, Helix BioPharma had 1 more articles in the media than Microbix Biosystems. MarketBeat recorded 1 mentions for Helix BioPharma and 0 mentions for Microbix Biosystems. Helix BioPharma's average media sentiment score of 1.08 beat Microbix Biosystems' score of 0.00 indicating that Helix BioPharma is being referred to more favorably in the media.

Company Overall Sentiment
Helix BioPharma Positive
Microbix Biosystems Neutral

0.0% of Helix BioPharma shares are held by institutional investors. Comparatively, 0.2% of Microbix Biosystems shares are held by institutional investors. 2.2% of Helix BioPharma shares are held by insiders. Comparatively, 14.0% of Microbix Biosystems shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Microbix Biosystems beats Helix BioPharma on 9 of the 12 factors compared between the two stocks.

How does Microbix Biosystems compare to Scythian Biosciences?

Microbix Biosystems (TSE:MBX) and Scythian Biosciences (CVE:SCYB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

Scythian Biosciences has a net margin of 0.00% compared to Microbix Biosystems' net margin of -38.62%. Scythian Biosciences' return on equity of 0.00% beat Microbix Biosystems' return on equity.

Company Net Margins Return on Equity Return on Assets
Microbix Biosystems-38.62% -21.02% 3.82%
Scythian Biosciences N/A N/A N/A

In the previous week, Microbix Biosystems' average media sentiment score of 0.00 equaled Scythian Biosciences'average media sentiment score.

Company Overall Sentiment
Microbix Biosystems Neutral
Scythian Biosciences Neutral

Microbix Biosystems has higher revenue and earnings than Scythian Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Microbix BiosystemsC$14.81M2.78C$3.39M-C$0.04N/A
Scythian BiosciencesN/AN/AN/AN/AN/A

0.2% of Microbix Biosystems shares are held by institutional investors. 14.0% of Microbix Biosystems shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Microbix Biosystems beats Scythian Biosciences on 4 of the 6 factors compared between the two stocks.

How does Microbix Biosystems compare to 138267 (COM.TO)?

Microbix Biosystems (TSE:MBX) and 138267 (COM.TO) (TSE:COM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

In the previous week, Microbix Biosystems' average media sentiment score of 0.00 equaled 138267 (COM.TO)'saverage media sentiment score.

Company Overall Sentiment
Microbix Biosystems Neutral
138267 (COM.TO) Neutral

Microbix Biosystems has higher revenue and earnings than 138267 (COM.TO).

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Microbix BiosystemsC$14.81M2.78C$3.39M-C$0.04N/A
138267 (COM.TO)N/AN/AN/AN/AN/A

0.2% of Microbix Biosystems shares are held by institutional investors. 14.0% of Microbix Biosystems shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

138267 (COM.TO) has a net margin of 0.00% compared to Microbix Biosystems' net margin of -38.62%. 138267 (COM.TO)'s return on equity of 0.00% beat Microbix Biosystems' return on equity.

Company Net Margins Return on Equity Return on Assets
Microbix Biosystems-38.62% -21.02% 3.82%
138267 (COM.TO) N/A N/A N/A

Summary

Microbix Biosystems beats 138267 (COM.TO) on 4 of the 6 factors compared between the two stocks.

How does Microbix Biosystems compare to Novoheart?

Microbix Biosystems (TSE:MBX) and Novoheart (CVE:NVH) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

Novoheart has a net margin of 0.00% compared to Microbix Biosystems' net margin of -38.62%. Novoheart's return on equity of 0.00% beat Microbix Biosystems' return on equity.

Company Net Margins Return on Equity Return on Assets
Microbix Biosystems-38.62% -21.02% 3.82%
Novoheart N/A N/A N/A

In the previous week, Microbix Biosystems' average media sentiment score of 0.00 equaled Novoheart'saverage media sentiment score.

Company Overall Sentiment
Microbix Biosystems Neutral
Novoheart Neutral

0.2% of Microbix Biosystems shares are owned by institutional investors. 14.0% of Microbix Biosystems shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Microbix Biosystems has higher revenue and earnings than Novoheart. Novoheart is trading at a lower price-to-earnings ratio than Microbix Biosystems, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Microbix BiosystemsC$14.81M2.78C$3.39M-C$0.04N/A
NovoheartC$423.50K236.08-C$7.17M-C$0.04N/A

Summary

Microbix Biosystems beats Novoheart on 6 of the 10 factors compared between the two stocks.

How does Microbix Biosystems compare to IntelGenx Technologies?

Microbix Biosystems (TSE:MBX) and IntelGenx Technologies (CVE:IGX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

In the previous week, Microbix Biosystems' average media sentiment score of 0.00 equaled IntelGenx Technologies'average media sentiment score.

Company Overall Sentiment
Microbix Biosystems Neutral
IntelGenx Technologies Neutral

IntelGenx Technologies has a net margin of 0.00% compared to Microbix Biosystems' net margin of -38.62%. IntelGenx Technologies' return on equity of 0.00% beat Microbix Biosystems' return on equity.

Company Net Margins Return on Equity Return on Assets
Microbix Biosystems-38.62% -21.02% 3.82%
IntelGenx Technologies N/A N/A N/A

0.2% of Microbix Biosystems shares are owned by institutional investors. 14.0% of Microbix Biosystems shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Microbix Biosystems has higher revenue and earnings than IntelGenx Technologies. IntelGenx Technologies is trading at a lower price-to-earnings ratio than Microbix Biosystems, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Microbix BiosystemsC$14.81M2.78C$3.39M-C$0.04N/A
IntelGenx TechnologiesC$1.75M49.95-C$11.74M-C$0.08N/A

Summary

Microbix Biosystems beats IntelGenx Technologies on 7 of the 10 factors compared between the two stocks.

Get Microbix Biosystems News Delivered to You Automatically

Sign up to receive the latest news and ratings for MBX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MBX vs. The Competition

Export
MetricMicrobix BiosystemsBiotechnology IndustryMedical SectorTSE Exchange
Market CapC$41.25MC$445.63MC$6.52BC$12.19B
Dividend Yield2.30%3.88%2.67%6.19%
P/E Ratio-7.323.1924.0036.94
Price / Sales2.786,464.11514.3610.45
Price / Cash4.1313.1327.4882.29
Price / Book1.6586.7510.544.47
Net IncomeC$3.39M-C$96.07MC$3.57BC$299.09M
7 Day Performance11.11%0.09%0.60%0.65%
1 Month Performance33.33%-0.27%1.56%-0.08%
1 Year Performance-1.64%56.11%25.42%41.90%

Microbix Biosystems Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MBX
Microbix Biosystems
N/AC$0.30
flat		N/A-1.6%C$41.25MC$14.81MN/AN/A
HBP
Helix BioPharma
N/AC$1.58
+3.9%		N/AN/AC$120.68MN/AN/A9
SCYB
Scythian Biosciences
N/AC$3.49
-5.9%		N/A+0.0%C$102.38MN/AN/AN/A
COM
138267 (COM.TO)
N/AN/AN/AN/AC$102.19MN/AN/AN/A
NVH
Novoheart
N/AC$0.53
+1.9%		N/A+0.0%C$99.98MC$423.50KN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:MBX) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel